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Abstract
Nanoporous adsorbents are promisingmaterials to augment the efﬁcacy of haemodialysis for the
treatment of end stage renal diseasewheremortality rates remain unacceptably highdespite
improvements inmembrane technology.Complications are linked in part to inefﬁcient removal of
protein bound andhighmolecularweight uraemic toxins includingkeymarkermolecules albumin
bound indoxyl sulphate (IS) andp-cresyl sulphate (PCS) and large inﬂammatory cytokines such as IL-6.
The following study describes the assessment of a nanoporous activated carbonmonolith produced
using a novel binder synthesis route for scale up as an in line device to augment haemodialysis through
adsorption of these toxins. Small and largemonolithswere synthesised using anoptimised ratio of lignin
binder to porous resinof 1 in 4. Smallmonoliths showing combined signiﬁcant IS, p-CS and IL-6
adsorptionwere used tomeasure haemocompatibility in an ex vivohealthy donorbloodperfusion
model, assessing coagulation, platelet, granulocyte, T cells and complement activation, haemolysis,
adsorption of electrolytes andplasmaproteins. The smallmonolithswere tested in a naive ratmodel and
showed stable blood gas values, bloodpressure, blood biochemistry and the absence of coagulopathies.
Thesemonolithswere scaled up to a clinically relevant size andwere able tomaintain adsorptionof
protein bounduraemic toxins IS, PCS andhighmolecularweight cytokinesTNF-α and IL-6 over
240minusing aﬂow rate of 300mlmin−1without platelet activation. The nanoporousmonolithswhere
haemocompatible and retained adsorptive efﬁcacy on scale upwithnegligible pressure drop across the
system indicatingpotential for use as an in-linedevice to improve haemodialysis efﬁcacy by adsorption
of otherwise poorly removeduraemic toxins.
1. Introduction
Nanoporous adsorbents offer a potential method by
which to address the life-reducing complications
associated with poor removal of protein bound and
high molecular weight uraemic toxins during haemo-
dialysis. Whilst more than two million patients with
end stage renal disease (ESRD) are treated by haemo-
dialysis worldwide mortality rates remain high.
Almost half of all patients who receive a diagnosis of
ESRD die within three years, most commonly as a
result of cardiovascular co-morbidity followed by
infection [1–4]. Haemodialysis is a life sustaining
therapy and an efﬁcient method for removing excess
ﬂuid and highly water soluble small molecules such as
ionic solutes and urea from blood. Urea is known to
hydrolyse into cyanate and form carbamylated hae-
moglobin [5–8] and other carbamylated proteins and
lipoproteins. However, there is debate as to whether
urea is a ‘uraemic’ toxin or whether its use as a marker
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of dialysis adequacy actually correlates with adequate
removal of uraemic toxins with the most damaging
effects on tissue physiology [9, 10]. Urea is rapidly
cleared during standard haemodialysis whereas other
uraemic retention solutes, particularly protein bound
and high molecular weight molecules, are minimally
cleared resulting in retention in ESRD patients [11].
Indoxyl sulphate (IS) and p-cresyl sulphate (PCS) are
protein bound uraemic toxins derived from protein
metabolism [12]. They have been shown, both within
in vitro and in animal models, to cause endothelial
damage and cardiovascular disease, and are associated
with increased mortality in ESRD patients [12–17]. To
date a suitable method to remove these and the many
other poorly removed protein bound and high mole-
cular uraemic toxins [17] remains to be found [11, 18].
Addition of an adsorption device into the standard
haemodialysis circuit has great potential to improve
removal of such toxins [2, 19–23]. Synthetic, activated
carbon adsorbents offer considerable advantages over
other polymer based systems. They outperform other
adsorbents through the existence of a highly developed
internal surface area which is suitable for non-speciﬁc
adsorption of predominantly hydrophobic, organic
molecules. Early studies using various granular AC
formulations from a range of natural sources showed
some success but were ultimately constrained by vari-
able performance, poor haemocompatibility particu-
larly related to platelet loss, pressure drop and poor
adsorption of larger biological molecules when coated
[24–31]. Advances in production technology using
synthetic pre-cursors have improved activated carbon
performance through carefully controlled formula-
tion, carbonisation and activation procedures allow-
ing the production of mechanically strongmicrobeads
with an internal surface area of over 1500 m2 g−1
[32–34]. Additionally it is possible to signiﬁcantly
increase capacity for the removal of protein bound and
high molecular weight uraemic toxins through the
development of nanopores with diameter in the range
of 10–100 nm [35–38]. This structure can be main-
tained and potential for pressure drop reduced by the
production of activated carbon monoliths, formed as
extruded cylinders with numerous micro-diameter
channels along which blood ﬂows.We have previously
shown that nanoporous activated carbon monoliths
can adsorb protein bound uraemic and high mole-
cular weight toxins which are poorly removed by hae-
modialysis alone [39]. However, a monolith synthesis
route which enabled the production ofmonoliths with
attrition resistance and adsorptive capacity on scale up
to a clinically relevant size was not possible using the
previous synthesis route. The aim of the current study
was to assess monoliths produced by a novel lignin
binder route for haemocompatibility using ex vivo
healthy donor and a niave rat haemoperfusion model.
Maintenance of nanoporosity and adsorptive capacity
on scale up was then assessed with the ultimate goal
of providing a potential augmentation strategy for
haemodialysis.
2.Materials andmethods
2.1.Monolith synthesis
Monoliths were synthesised using a novolac phenol-
formaldehyde resin pre-cursor dissolved in a pore-
forming solvent, ethylene glycol, together with a cross-
linking agent, hexamethylenetetramine, and lignin bin-
der. The ratio of lignin binder to nanoporous resin was
optimised to a wt% ratio of 25:75. The pre-polymer
solution was cured and the resulting resin cake was
crushed, washed and dried to remove excess pore former
then milled and formed into a dough for extrusion. The
resulting monoliths were carbonised at 700 °C and
activated in carbon dioxide at temperatures of up to
880 °C. Nanoporosity was controlled primarily by initial
resin pore-former composition and the unique phase
separation that occurs during the curing stage. Small
monoliths were prepared with a diameter of 7mm,
length of 95mm and contained 30 square micro-
channels. Large monoliths were prepared with a dia-
meter of 30mm and length of 225mm and contained
600 square micro-channels with a diameter of 300μm.
The monoliths were encased in heat shrink polyoleﬁn
tubes supplied by RS Components Ltd (Northampton-
shire, UK). The process sealed Leuer lock ﬁttings to the
ends of the monoliths prior to the perfusion studies
(ﬁgures 1(a) and (b)).
2.2. Physical characterisation of small and large
monoliths
The surface and internal porous morphology of the
resultant monolithic materials were characterised by
scanning electron microscopy (SEM) using a Sigma
ﬁeld emission gun-SEM microscope (Carl Zeiss NTS,
Cambridge, UK). The deﬁnition of pore size in
nanoporous materials according to the International
Union of Pure and Applied Chemistry is that micro-
pores are smaller than 2 nm in diameter, mesopores
2–50 nm and macropores larger than 50 nm. The
carbons used in this study were predominantly micro-
macroporous. Prior to measurement, the hierarchi-
cally porous monolithic materials were dried under
vacuum at 150 °C overnight. The pore size distribu-
tion data was determined using a PoreMaster mercury
intrusion porosimeter (Quantachrome Instruments
Ltd, Hook, UK). Surface area was determined using an
Autosorb-1 gas sorption analyser, (Quantachrome
Instruments, USA) using Quantachrome data analysis
software (Quantachrome ASiQwin) and the Brunauer,
Emmett andTeller (BET)method.
2.3. Adsorption ofmarker uraemic toxins by the
smallmonoliths
The small monoliths were primed with saline solution
for 30 min at a ﬂow rate of 5 ml min−1. A 20 ml
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volume of fresh frozen human plasma (Cambridge
Bioscience) was spiked with IS (125 μM), PCS
(250 μM) and IL6 (1 ng ml−1). The spiked plasma
solution underwent continuous circulation through
the monoliths and samples were collected over time.
IS and PCS concentrations were measured by HPLC
using a method described in [39] and IL6 concentra-
tion was measured by ELISA according to manufac-
turer’s instructions using a plasma dilution of 1:5 (BD
Biosciences).
2.4.Haemocompatibility testing of smallmonoliths
Haemocompatibility studies were carried out accord-
ing to ISO standard 10993-4:2002 (E) using freshly
drawn healthy donor blood from an anonymised
healthy donor database held by the NIHR Brighton &
Sussex Clinical Research Facility using informed con-
sent protocols (UK National Research Ethics System
(NRES) Committee South East Coast—Brighton and
Sussex REC reference 13/LO/1058). The smallmono-
liths (7 mm×95 mm with 30 micro-channels) were
pre-conditioned with saline (0.9% NaCl) for 30 min
prior to continuous circulation of 20 ml of healthy
donor blood through the monoliths for 60 min at a
ﬂow rate of 5 ml min−1 (ﬁgure 1(c)). Plasma was
prepared by centrifugation of blood samples at
3500 rpm for 15 min.
2.5. Complement activation
The presence of C3a, C4a and C5a was measured in
plasma prepared from EDTA anticoagulated blood by
enzyme linked immunosorbent assay (ELISA) (BD
Biosciences). ELISAs were carried out according to
manufacturer’s instructions issuing a 1 in 2000
dilution for C3a andC4a and a 1 in 40 dilution for C5a.
2.6. Platelet activation
The presence of PAC-1 and CD62 platelet activation
markers (BD Biosciences UK) was measured in
sodium citrate anticoagulated donor blood samples
pre- and post- perfusion throughmonolith and tubing
only controls using ﬂow cytometry. The ﬁrst 2 ml
blood was drawn and discarded. 2 ml of blood
incubated with ADP (2 μM) (Sigma Aldrich, UK) for
5 min was used as a positive control. Fresh whole
blood samples (5 μl) were incubated in the dark with
PE/CD61 (10 μl), allophycocyanin (APC)/D62P
(10 μl) and ﬂuorescein isothiocyanate (FITC)/PAC-1
(10 μl) antibody cocktail for 20 min, ﬁxed using
chilled 1% paraformaldehyde in PBS (1 ml) for 30 min
at 4 °C and analysed using an Accuri C6 ﬂow
Figure 1. (a) Small and largemonoliths were produced using a novel lignin binder routewith dimensions of 0.7 cm×9.5 cm and
2.8×22.5 cm (diameter by length) andmicrochannel numbers of 30 channels and 600 channels respectively. (b)Themonolithswere
encased in heat shrink polyoleﬁn tubes. (c) In vitro plasma andwhole blood experiments were conducted, perfusing ﬂuid through the
monolithmicrochannels at aﬂow rate of 5 ml min−1 for the smallmonolith studies and 300 ml min−1 for the largemonolith studies.
(d)Anaive rat haemoperfusionmodel was used to carry out an in vivo safety assessment of the smallmonoliths.
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cytometer and BD CSampler software (version
1.0.264.21). The ﬂow cytometer was set to slow ﬂow
rate, with a forward scatter (FSC) threshold of 10 000
to collect 10 000 events on the platelet gate.
2.7. Granulocyte activation
Granulocyte activation was measured by testing
lithium heparin anticoagulated donor blood samples
for the presence of CD14/CD11bmarkers (Biolegend,
UK) using ﬂow cytometry. Positive control samples
were prepared by incubating blood samples with
interleukin 6 (IL-6) (50 ng ml−1) and interleukin 8
(IL-8) (50 ng ml−1) for 60 min. Blood samples (100 μl)
were incubated with PE/CD14 (20 μl) and APC/
CD11b (20 μl) antibody cocktails for 20 min. Stained
blood samples were incubated with lyse/ﬁx buffer
(1.5 ml) in the dark for 30 min prior to centrifugation
at 600 g for 6 min, removal of supernatant and
washing of cells in 2 ml stain buffer. Cells were pelleted
and resuspended in 300 μl stain buffer for analysis
using ﬂow cytometry. The ﬂow cytometer was set to
medium ﬂow rate, with a FSC threshold of 80 000 to
collect 10 000 events.
2.8. T cell activation
T cell activation was assessed in EDTA anticoagulated
blood samples by measuring the activation of STAT3
and STAT5 intracellular phosphorylation pathways
using ﬂow cytometry. Whole blood samples (200 μl)
were lysed, permeabilised and stained by incubating
with PerCP/CD3, Alexa488/CD8, PE/CD4 antibody
cocktail (20 μl) and Alexa647/STAT3 or STAT5
(20 μl) for 1 h. Positive control samples were prepared
using an IL-6 (50 ng ml−1) and IL-8 (50 ng ml−1) spike
for STAT3 activation and interleukin 2 (IL-2)
(50 ng ml−1) spike for STAT5 activation followed by
incubation for 60 min. Cells were washed and resus-
pended in 200 μl stain buffer for analysis using ﬂow
cytometrywith setting as for the granulocyte activation
assay.
2.9. Adsorption of uraemic toxins by the large
monoliths
Large monoliths (n=3) were pre-conditioned with
intravenous infusion saline solution (0.9% NaCl,
0.15% KCl and 0.2% MgCl) (Baxter) for 30 min. A
400 ml volume of blood, anti-coagulated with sodium
heparin and commercially supplied by Cambridge
Biosciences, was spiked with 1000 pg ml−1 IL-6 and
tumor necrosis factor alpha (TNF-α), 125 μM IS and
250 μM PCS and continuously perfused through the
monolith or tubing controls for 60 min at aﬂow rate of
300 ml min−1 (LaboVAR 225 pump, Möller Medical
GmbH Fulda Germany). Samples were collected after
0, 5, 15, 30, 45, 60, 90 min. A second study extended
sampling to 240 min. IS and PCS concentrations were
measured by HPLC using a method described in [39]
and IL6/TNF-α concentration was measured by
ELISA according to manufacturer’s instructions using
a dilution of 1:5 (BD Biosciences). Platelet activation
was measured in the plasma derived from the timed
blood samples as described in section 2.5.
2.10. In vivo safety assessment of smallmonoliths
All studies were conducted under the governance of
the UK Animals in Scientiﬁc Procedures Act (1986,
amended 2012), with full local ethical approval.
Animals were allowed free access to food and water
prior to the study and housed under a 12 h light/dark
cycle at 20 °C (±2 °C). Adult male Sprague-Dawley
rats (250–300 g, Charles River UK)were anaesthetised
under isoﬂuorane (induction at 5% in oxygen, main-
tenance at 1.5% in air for the duration of the study)
and had catheters placed in the left carotid artery and
right jugular vein.Mean arterial pressure was recorded
at hourly intervals (Biopac US) and core body temper-
ature recorded throughout the study. To maintain
body temperature, the animals were maintained on
regulated heat mats and covered with insulated
materials as required.
Blood samples were collected into lithium heparin
coated tubes for blood gas analysis (Siemens Medical
Diagnostics, UK) and plasma biochemistry prior to,
and at hourly intervals throughout the study. After an
initial 30 min stabilisation period, the arterial catheter
was connected to a carbon monolith (approximately
10 cm by 1 cm (length×diameter)) via a peristaltic
pump (ﬁgure 1(d)). The blood was then returned to
the animal via the catheter placed into the jugular vein.
Flow rates throughout the 2 h treatment period were
set at 2 ml min−1 with the total circuit volume not
exceeding 10% of the circulating blood volume of the
animal (ca 3 ml maximum). The circuit was pre ﬁlled
with heparinised saline solution (1000 U l −1), with a
saline bolus (ca 2 ml) administered to the animal at the
start of treatment to prevent hypotension. At the ter-
mination of the study, blood and tissue samples were
collected under terminal anaesthesia. Blood samples
for biochemistry were stored on ice before centrifuga-
tion (3500 rpm, 10 min, 4 °C) and storage at −80 °C.
Plasma biochemistry (glucose, urea, albumin, total
protein, ALT, AST, creatinine) was assessed using an
automated COBAS system (Roche, UK) following
manufacturer’s instructions.
2.11. Statistical analysis
Statistical analysis was carried out using GraphPad
Prism 6.05 software and two-way ANOVA with
Tukey’smultiple comparison tests.
3. Results
3.1. Physical characterisation of the large and small
monoliths
The synthesis and activation process resulted in a
well-deﬁned distribution of transport microchannels
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running in parallel along the length of the monoliths
(ﬁgures 2(a)–(c)). The internal structure of the carbon
monolith walls was visible in the SEMs as larger
macroporous and smaller nanoporous domains. The
mercury porosimetry pore size distribution plot
indicated nanoporous domains in the 20–100 nm
range in both the small and largemonoliths withmean
peak porosity of 55.6 nm and 62.1 nm respectively
(ﬁgure 2(d)). The BET surface area was calculated
by gas nitrogen porosimetry to be 1117 m2 g−1 in
the small monoliths and 1056 m2 g−1 in the large
monoliths.
3.2. Adsorption ofmarker uraemic toxins by the
smallmonoliths
The small monoliths synthesised using a 25% lignin
binder were able to adsorb uraemic toxins IS and PCS,
reducing them to neglible levels and reduced IL-6
concentration by 80% (ﬁgure 3).
3.3.Haemocompatibility testing of the small
monoliths
3.3.1. Complement activation
Blood perfused through the small monoliths over time
did not cause signiﬁcant complement activation when
compared to the negative, tubing only control (p>0.05)
(ﬁgures 4(a)–(c)). Some complement activation was
observed at baseline and a slight increase occurred in
both the monolith and tubing only controls over the
60min perfusion cycle. However, this was signiﬁcantly
less than that of the zymosan A activated positive
controls in which complement fragment concentrations
increased from 1.5 to 4.1 ngml−1 for C3a (p<0.0001)
(ﬁgure 4(a)), 1.6 to 3.3 ngml−1 for C4a (p<0.05)
(ﬁgure 4(b)) and 3.9 to 43.5 pgml−1 for C5a
(p<0.0001) (ﬁgure 4(c)). C5a concentration detected in
the plasma was in the picogram range and signiﬁcantly
lower than that for C3a and C4a which was in the ng
range.
3.3.2. Platelet activation
A platelet sub-population was isolated from the total
blood cell population using a R-Phycoerythrin (PE)
ﬂuorophore conjugated CD61 antibody against the
platelet surface antigen glycoprotein IIIa. Within
this platelet sub-population activated platelets were
detected using a FITC ﬂuorophore conjugated PAC-1
antibody and an APC conjugated CD62p antibody
(ﬁgures 4(d) and (e)). No signiﬁcant platelet activation
occurred following 60 min of perfusion through the
small monoliths and the tubing only controls. No
signiﬁcant difference in the percentage of PAC-1 and
CD62P positive platelets was observed when compar-
ing the monolith and tubing only control following
60 min continuous ﬁltration through the ex vivo
circuit. In contrast, the PMA (200 nM) spike
induced signiﬁcant platelet activation (SEM±, n=3,
p<0.0001).
Figure 2. (a) Scanning electronmicrograph showingmicrochannel geometry and (b)nanoporous domains within thewalls of the
small and largemonoliths. (c)Mercury pore size distribution plots indicated consistentmeso-macroporosity in the small and large
monoliths with amean pore size of 56 nmand 62 nm respectively and SBET surface area calculated by gas nitrogen porosimetry of
1117 and 1056 m2 g−1 respectively.
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3.3.3. Granulocyte activation
No signiﬁcant difference in granulocyte activation was
observed between the monolith and tubing only
controls following 60 min perfusion, although granu-
locyte activation did occur in both circuits (data not
shown). Granulocyte activation, measured by elevated
CD11b expression, occurred over 30 and 60 min blood
perfusion through both monoliths and control but
was less than that measured in the cytokine stimulated
positive control (SEM±, n=3). 8% granulocyte
activation was measured at baseline, 20±4% after
30 min perfusion and 70±13% after 60 min perfu-
sion in both the small monolith and tubing only
samples.
3.3.4. T cell activation
The PE conjugated CD3 antibody was used to identify
the T cell subpopulation. Alexa 647 conjugated STAT3
and STAT5 antibodies were used to identify the post-
perfusion, activated T cells, IL6/IL8 (50 ng ml−1)
activated STAT3 positive control and IL2 activated
STAT5 positive control (ﬁgures 4(f) and (g)). No up
regulation of intracellular STAT phosphorylation
pathways was detected following blood perfusion
through the small monoliths over 60 min. Negligible
levels of STAT3 phosphorylation and STAT5 phos-
phorylation and levels of 10%–20% were detected in
the pre- and post-perfusion monolith samples, tubing
only control samples and time 0 cytokine spiked
positive controls. A signiﬁcant increase in the cytokine
stimulated positive control samples occurred over
60 min. 91±3% STAT5 T-cell activation and
64±2% STAT3 T-cell activation was detected. No
signiﬁcant T cell activation, measured by phosphory-
lated STAT3 and STAT5 protein expression, was
observed following blood perfusion through the
monoliths over 60 min compared to the cytokine
(50 ng ml−1) stimulated controls (SEM±, n=3,
p<0.0001).
3.3.5. Blood biochemistry and coagulometry
Haemoglobin and haematocrit values, blood cell count,
ionic solutes, urea, creatinine, total protein, albumin,
ﬁbrinogen and coagulometry measures remained in
normal range and were not removed signiﬁcantly by
blood perfusion through the small monoliths (table 1).
Limited reduction in platelet count, total protein and
albumin concentration occurred following blood perfu-
sion through themonoliths. Platelet countdropped from
261±54 to 230±75×109 cells ml−1 post-monolith
perfusion.The total protein concentrationdropped from
75.7±2.5 to 64±2 g l−1 and albumin concentration
dropped from 46±1 to 39.7±0.6 g l−1, all remaining
in normal concentration range. A signiﬁcant reduction
in creatinine concentration occurred, reducing from
66.7±13.6 to 17.7±6μmol l−1. No change in acti-
vated partial thromboplastin times (APPT) or Interna-
tional normalised ratio (INR)were observed. Fibrinogen
concentration reduced from 2.8 g l−1 in the pre-perfu-
sion blood samples to 2.1 g l−1 in the monolith post
perfusion samples but remained within the normal
reference range.
3.4. Adsorption of uraemic toxins by the large
monoliths
IS and PCS concentrations were reduced from 125 and
250 μM to negligible levels following perfusion
through the large, 30 mm diameter monoliths for
90 min compared to the tubing only positive controls
where IS and PCS concentration remained unchanged
(ﬁgures 5(a)–(d)). The monoliths adsorbed IL-6 and
TNF-α, signiﬁcantly reducing IL-6 concentration
from 711 to 162 pg ml−1 and TNF-α from 1070 to
441 pg ml−1 over a 90 min perfusion cycle. A platelet
activation study showed no signiﬁcant activation of
platelets over 90 min of perfusion through the mono-
liths and controls (ﬁgure 6). A further study extending
the perfusion cycle to 240 min showed continued
reduction in IS, PCS and IL-6 (ﬁgure 7).
3.5. In vivo safety assessment of smallmonoliths
The in vivo monolith perfusion safety study indicated
no major concerns with regard to biocompatibility.
None of the studies conducted showed any evidence of
coagulopathies, either in terms of excess bleeding or
clotting abnormalities. The circuit was pre-ﬁlled with
Figure 3.Adsorption of IS (125 μM), p-CS (250 μM) and IL-6 (1000 pg ml−1) from spiked fresh frozen humanplasma over time by
the smallmonoliths synthesised using a 25:75%wt ratio of lignin to nanoporous resin (n=3,mean ± SEM).
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heparinised saline, thought there was no evidence that
themonolith removed heparin form the circuit. Blood
gas values remained stable throughout the duration of
the study (table 2), with only the bicarbonate level
showing a moderate decline over the two-hour treat-
ment period. This may be due to the amount of saline
Figure 4.Perfusion of freshly drawnhealthy donor blood through the smallmonoliths over 60 min stimulated no signiﬁcant
complement activationmeasured using (a)C3a (b)C4a and (c)C5a activationmarkers, no signiﬁcant platelet activationmeasured
using (d)PAC-1 and (e)CD62P activationmarkers and no signiﬁcant T cell activation,measured using phosphorylated (f) STAT3 and
(g) STAT5 protein expressionwhen compared to tubing only controls in comparison to the zymosanA, PMAand cytokine stimulated
positive controls (mean ± SEM, n=3), ** p<0.01, **** p<0.0001.
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administered to the animal to replace blood volume.
Plasma biochemistry values showed decreases in
albumin and total protein levels, whichmay have been
due to adsorbance by the column, but are also as a
result of the haemodilution caused by connection to
the saline ﬁlled circuit and additional crystalloid
boluses. Creatinine values rose at the end of the study,
which may indicate a small degree of haemolysis
within the circuit resulting from the continued action
of the peristaltic pump. Although this difference in
Figure 5.Healthy donor blood spikedwith IS (125 μM), p-CS (250 μM), IL-6 (1000 pg ml−1) andTNF(1000 pg ml−1) and perfused
through the largemonoliths at aﬂow rate of 300 ml min−1. (a) IS (b) p-CS (c) IL-6 and (d)TNF-α concentrationwas signiﬁcantly
reduced following 90 min continuous ﬁltration compared to the tubing only control (SEM±, n=3), *p<0.05.
Table 1.Healthy donor blood perfused through the smallmonoliths at 5 ml min−1 for 90 min did not
produce signiﬁcant changes in blood cell count (WBC,RBC, PLT), haematocrit (HCT) and haemoglobin
(HB)measures of haemolysis, urea, creatinine, total protein andAPPT and INRmeasures of coagulation
compared to tubing only controls (mean ± SD, n=3).
Pre-perfusion Monolith Tubing Normal range
HB (g l−1) 140.8±16.8 137.2±30.4 132.8±26.6 115–165
WBC×109 cell ml−1 7.4±1.5 7.4±2.1 7.9±2.2 4.0–11.0
PLT×109 cell ml−1 261±54 230±75 288±111 150–450
RBC×1012 cell ml−1 4.76±0.59 4.57±1.09 4.40±0.92 3080–5.80
HCT (l l −1) 0.416±0.049 0.381±0.095 0.365±0.073 0.350–0.470
Sodium (mmol l−1) 139±2 139.7±0.6 137.0±1.7 135–146
Potassium (mmol l−1) 4.2±0.2 4.1±0.1 4.5±0.2 3.2–5.1
Urea (mmol l−1) 4.8±1.8 3.8±1.4 4.8±1.7 1.7–8.3
Creatinine (μmol l−1) 66.7±13.6 17.7±5.0 69.0±14.7 62–106
Total protein (g l−1) 75.7±2.5 64±2 74.7±1.5 66–87
Albumin (g l−1) 46±1 39.7±0.6 45.3±0.6 34–48
Fibrinogen (g l−1) 2.8±0.5 2.1±0.4 2.8±0.6 2.0–4.0
APTT (S) 1.0±0.1 1.0±0.1 0.9±0.1 0.8–1.2
INR 0.1 1.1±0.1 1.0±0.0 0.8–1.2
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creatinine is signiﬁcant, the values are not excessively
high (table 2). Mean arterial blood pressure remained
stable throughout the duration of the study, indicating
that the animals tolerated the procedure well.
4.Discussion
The study provides evidence to support the haemo-
compatibility and efﬁcacy of a scaleable nanoporous
activated carbon monolith device for potential use to
augment current haemodialysis therapy. A range of
haemocompatibility tests using healthy donor blood
samples and a small animal blood perfusionmodelling
study demonstrated that themonoliths are safe for use
in direct blood contact. A novel lignin binder synthesis
route was used to successfully scale up the device to a
clinically feasible size without reducing adsorptive
efﬁcacy for marker protein bound and high molecular
weight uraemic toxins. Whilst no previous studies on
nanoporous activated carbon monoliths with the
porous range demonstrated in this study have been
described, in vitro study data exists for carbons in bead
form include carbide derived carbons, phenolic resin
derived activated carbons and carbon incorporated
into a mixed matrix hallow ﬁbre membrane form
[40–42]. The beads showed some efﬁcacy in spiked
plasma studies but offer no solution to the challenges
of direct blood contact and pressure drop. Mixed
membrane carbon incorporation offers an interesting
alternative but may limit contact area for sufﬁcient
adsorption of high molecular weight molecules. In
mixedmembrane form signiﬁcant IS andPCS removal
was reported but no data was reported for high
molecular weight species potentially because the
membrane cut off limits direct contact. Previous
studies comparing synthetic resin derived carbon bead
activation burn off and adsorptive efﬁcacy reported
reduction of high molecular weight cytokine TNF
matching that shown previously for CDCs but data is
limited to batch adsorption studies from plasma.
Within the current study a phenolic resin derived
activated carbon monolith rather than bead based
device was shown to reduce IS and PCS levels in spiked
whole blood to negligible levels and IL6 andTNF levels
by 80% and 60% respectively indicating a scaleable
efﬁcacy compared to bead based alternatives. The
monolith design solves issues of haemocompatibility
and pressure drop across the adsorbent device without
resorting to coating with potential subsequent reduc-
tion in the molecular weight cut-off and adsorptive
proﬁle.
There are many advantages in adapting the acti-
vated carbon form to a monolithic structure for direct
blood perfusion but alsomany challenges inmaintain-
ing porous proﬁle and adsorptive efﬁcacy. Previous
tests using a small monolith prototype and haemodia-
lysis patient blood samples indicated that adsorption
of protein bound and middle molecules was depen-
dent on creating nanopores in the 2–100 nm range
since adsorption of these solutes in carbon monoliths
with narrow nanopores of <2 nm was limited [39].
The challenge in scaling up the monolith was to main-
tain nanoporosity but also to design the monolith
channel parameters to balance maximum adsorption
with appropriate internal ﬂuid dynamics [43]. This
was achieved in the current device iteration by using a
constant 0.3 mm microchannel channel size. A short
diffusion distance was provided for access to the inter-
nal porous surface area in the walls of the monolith
and a micro-channel structure capable of minimising
shear stress, maintaining laminar ﬂow and thus redu-
cing red blood cell fragility, haemolysis, platelet activa-
tion and thrombus formation. Previous studies with
Figure 6.Perfusion of healthy donor blood for 90 min through the largemonoliths at haemodialysis ﬂow rates did not stimulate
platelet activation using (a)PAC-1 and (b)CD62P activationmarkers compared to tubing only controls. No signiﬁcant difference in
the percentage of PAC-1 andCD62P positive platelets was observedwhen comparing themonolith and tubing only control. In
contrast, the PMA (200 nM) spike induced signiﬁcant platelet activation (SEM±, n=3), *** p<0.001.
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activated carbon granules containing narrow nano-
pores of <2 nm have highlighted the tendency for
excessive pressure drop, platelet consumption, albu-
min loss and potential for carbon ﬁnes release [30].
The introduction of a monolithic design was therefore
integral to minimise the tendency for ﬂow irregula-
rities, pressure drop and impact on blood cell fragility,
platelet loss and protein adhesion.
Binding of plasma proteins occurs as soon as blood
contacts a foreign surface. Dominant plasma proteins
albumin, ﬁbrinogen and IgG coat a surface immedi-
ately but with a dynamic exchange with other plasma
proteins over time [44]. Protein surface coating in the
extracorporeal circuit becomes problematic if proteins
are denatured and expose activation sites for inﬂam-
matory pathway activation or in some cases if a nega-
tively charged surface induces contact activation [44].
Protein surface adhesion may also form a passivating
layer, limiting any further inﬂammatory response. In
the current study blood albumin and ﬁbrinogen con-
centrations were reduced on contact with the mono-
liths. However, total protein, albumin and ﬁbrinogen
concentrations all remained within the normal refer-
ence range indicating a non-detrimental, dynamic,
adsorptive equilibrium for these dominant plasma
proteins over the initial time course of haemodialysis.
Adsorption of dominant plasma protein serum albu-
min (66 kDa) and ﬁbrinogen (340 kDa) did not pre-
vent adsorption of less concentrated high molecular
weight IL-6 (28 kDa) and TNF-α (52 kDa), present in
picogram quantities, and adsorbed predominantly
within the nanoporous domains of themonoliths. The
cause of this effect is not clear but could be related to
the different hydrophobic domains within the pro-
teins. AC is a hydrophobic adsorbent and it has been
reported that the TNF-α trimer undergoes reversible
dissociation into three monomeric units in contact
with hydrophobic surfaces and therefore smaller
molecules of IL-6 and TNF-α monomer (17 kDa)
could be adsorbed predominantly within the nano-
porous domains of the monoliths inaccessible to albu-
min [45]. Results conﬁrm no signiﬁcant impact on
total protein, electrolyte and haemolysis parameters
using healthy donor blood perfused through the small
monoliths over time. Albumin and platelet reduction
was slight using the healthy blood samples in contrast
to a previous study using post-haemodialysis blood
samples where a greater reduction in platelet count
and albumin concentration was observed [39]. A
number of additional variables including differences
in blood sample handling and monolith formulation
may have inﬂuenced the heightened propensity for
haemodialysis blood sample proteins and platelets
to adhere but the results also support the premise
that haemodialysis patient blood is primed for
inﬂammation.
The haemocompatibility tests were carried out on
the small monolith prototypes according to ISO 10993
for blood contacting medical devices assessing platelet
activation, granulocyte activation, activation of t-cell
intracellular phosphorylation pathways for STAT3 and
STAT5 using ﬂow cytometry, complement fragment
concentration for C3a, C4a, C5a using ELISA and coa-
gulometry assays measuring pro-thrombin, APPT clot-
ting times and ﬁbrinogen concentration. The signal
transducer and activator of transcription (STAT) family
are a group of proteins activated by cytokines and
growth factors through receptor associated kinase
phosphorylation followed by dimerisation, transloca-
tion into the nucleus and transcription of genes related
to cell proliferation and the inﬂammatory response.
They were used in this study as the earliest indicator of
T-cell activation on inﬂammatory stimulus by the
monoliths. Some complement activation and in part-
icular granulocyte activationwas detected at the 60min
time point for both monolith and tubing only negative
controls. Complement activation is known to occur
routinely on exposure to a foreign surface within hae-
modialysis, cardiopulmonary bypass and apheresis via
the alternative pathway [46–48]. The small, cationic
peptides C3a, C4a and C5a are anaphylatoxins which
are free in the plasma and bind to neutrophils and
monocytes to promote ROS production, cytokine
release and cell hyper-adhesion. Activation was no
Figure 7. (a) Indoxyl sulphate, p-cresyl sulphate (125 μMIS, 250 μMp-CS spike) and (b) IL-6 (1 ng ml−1 spike) remaining following
240 min spiked blood perfusion through the largemonoliths (mean ± SEM, n=8).
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more than the tubing only controls and was markedly
limited when compared to the zymozan A activated,
positive control blood samples, indicating that the arti-
ﬁcial surfaces within the perfusion model itself and not
the monoliths promoted some activation of inﬂamma-
tory pathways.
The large monoliths maintained adsorptive efﬁ-
cacy for the uraemic toxins IS and PCS and cytokines
IL-6 and TNF-α on scale up and at haemodialysis ﬂow
rates with minimal pressure drop. Further work is
required to establish breakthrough parameters and the
impact of rebound release on adsorption but the cur-
rent study indicates that an adsorptive equilibrium is
maintained over 4 h perfusion time. The broad spec-
trum adsorptive capacity of the activated nanoporous
carbonmonoliths for organic molecules indicates that
these monoliths will have great capacity to remove
other poorly removed protein bound and middle
molecule uraemic toxins from the growing family of
uraemic toxins known to remain after standard hae-
modialysis treatments and represented by these mar-
kermolecules.
In summary, whilst haemodialysis patients have
an immunosuppressive and altered haemostatic
balance so that blood cell fragility and inﬂammatory
response on contact with foreign surfaces will inevi-
tably be hypersensitised toward inﬂammation [49] the
results of the current study show that, using healthy
donor blood, a nanoporous activated carbon mono-
lith does not exacerbate blood cell activation accord-
ing to ISO 10993 haemocompatibility measures.
Haemocompatibility was also demonstrated using
an in vivo haemoperfusion safety model where no
disruption of blood biochemistry or coagulopathy
occurred. The scaled up device maintained the
internal nanoporous structure necessary to augment
haemodialysis efﬁcacy through broad spectrum
adsorption of small, protein bound and high mole-
cularweight uraemic toxins.
5. Conclusion
A novel lignin binder synthesis route has been used to
synthesise nanoporous activated carbon monoliths
with maintained adsorptive capacity for marker pro-
tein bound and high molecular weight toxins on scale
up and testing at haemodialysis ﬂow rates. These
toxins currently remain following haemodialysis and
contribute to poor survival related to cardiovascular
disease and infection. The carbonmonolith is safe and
shows good biocompatibility when tested in naive rats.
Such a device could potentially be used as an in-line
haemoperfusion device to sit in line with and augment
the clearance of uraemic toxins poorly removed by
standard haemodialysis.
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